| Allison Perry Mitchell, CNM | |
|
11102 Sunrise Blvd E Ste 110, South Hill, WA 98374-8846 | |
| (253) 697-3550 | |
| Not Available |
| Full Name | Allison Perry Mitchell |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 11102 Sunrise Blvd E Ste 110, South Hill, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508359225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | AP60958300 (Washington) | Primary |
| 207V00000X | Obstetrics & Gynecology | RN261772 (Georgia) | Secondary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis Corporation received CE-Marking approval for ExoSeal(TM) Vascular Closure Device in May 2010.
One such strain is the South African 501.V2 and UK B1.1.7 strains, which have been isolated from many countries and seem to spread faster than the ancestral strain. A preprint that recently appeared on the bioRxiv server reports the computational structure of this strain and the possible effect of the mutations on infectivity and neutralization.
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer, increasing progression-free survival.
Scientists are reporting a scientific basis for the long-standing belief that a widely used non-prescription drug in China and certain other countries can prevent and treat cataracts, a clouding of the lens of the eye that is a leading cause of vision loss worldwide. Their study appears in Inorganic Chemistry, an ACS journal.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allison Perry Mitchell, CNM 5120 N 9th St, Tacoma, WA 98406-2612 Ph: (808) 284-5288 | Allison Perry Mitchell, CNM 11102 Sunrise Blvd E Ste 110, South Hill, WA 98374-8846 Ph: (253) 697-3550 |
News Archive
New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis Corporation received CE-Marking approval for ExoSeal(TM) Vascular Closure Device in May 2010.
One such strain is the South African 501.V2 and UK B1.1.7 strains, which have been isolated from many countries and seem to spread faster than the ancestral strain. A preprint that recently appeared on the bioRxiv server reports the computational structure of this strain and the possible effect of the mutations on infectivity and neutralization.
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer, increasing progression-free survival.
Scientists are reporting a scientific basis for the long-standing belief that a widely used non-prescription drug in China and certain other countries can prevent and treat cataracts, a clouding of the lens of the eye that is a leading cause of vision loss worldwide. Their study appears in Inorganic Chemistry, an ACS journal.
› Verified 8 days ago